Browsing by Author Rischin, D.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2003Doxetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patientsBoyer, Michael; Clarke, Simon; Bishop, J F; Goh, B-C; Lehnert, M; McNeil, E; Millward, M J; Rischin, D.; Wong, J; Central Clinical School: Medicine; Western Clinical School: Westmead Millennium InstituteDoxetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients, Annals of Oncology, vol.14,(3),2003,pp 449-454
2010Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Studyvan Zandwijk, Nico; Allan, S; Baliko, Zoltan; Gridelli, C; Heigener, David; Krzakowski, Maciej; Reck, Martin; Rischin, D.; Concord Clinical School: ANZAC Research InstituteErlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study, Journal of Thoracic Oncology, vol.5, 10,pp 1616-1622
2011IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell CancerdeFazio, Anna; Anglesio, Michael S.; Australian Ovarian Cancer Study Group, (AOCSG); Balkwill, Frances; Birrer, Michael J.; Bowtell, David D L; Campbell, Ian G.; Chakravarty, Probir; Coward, Jermaine; Cowin, Prue; Friedlander, Michael L.; George, Joshy; Gilks, B; Gorringe, Kylie; House, Colin; Huntsman, David; Kalloger, Steve; Kulbe, Hagen; Lemech, Charlotte; Okamoto, Aikou; Power, Jeremy; Rischin, D.; Western Clinical School: Westmead Millennium InstituteIL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer, Clinical Cancer Research, vol.17, 8, 2011,pp 2538-2548
2002Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodiesClarke, Stephen; Millward, Michael; Ackland, Stephen P.; Garg, M. B.; Rischin, D.; Smith, J.; Toner, Guy C.; Zalcberg, John; Concord Clinical School: ANZAC Research Institute; MedicinePhase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibodies, Annals of Oncology, vol.13,(11),2002,pp 1810-1818
2002A phase II trial of ZD0473 in platinum-pretreated ovarian cancerBeale, Philip; Atkinson, R.J.; Bougnoux, P.; Cure, H.; Dirix, L.; Gore, M.E; Rischin, D.; Smit, W.M; Thomas, H.; Central Clinical School: MedicineA phase II trial of ZD0473 in platinum-pretreated ovarian cancer, European Journal Of Cancer, vol.38,(18),2002,pp 2416-2420
2002Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free intervalBeale, Philip; Atkinson, R.J.; Bougnoux, P.; Cure, H.; Dirix, L.; Gore, M.E; Rischin, D.; Smit, W.M; Thomas, H.; Central Clinical School: MedicineResults of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval, European Journal Of Cancer, vol.38,(supplement 8),2002,pp s7-s12
2005Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)Jackson, Michael; Corry, June; Denham, Jim; et al, various; Fisher, Richard; Kenny, Lizbeth Kenny; Macann, Andrew; Penniment, Michael; Peters, Lester; Poulsen, Michael; Rischin, D.; Central Clinical School: MedicineTirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02), Journal of Clinical Oncology, vol.23,(1),2005,pp 79-87